



Publikationen 2009 – 2011
Abteilung Makromolekulare Prodrugs
an der Klinik für Tumorbiologie

Dr. Felix Kratz

*Dr. Felix Kratz, Leiter der Abteilung Makromolekulare Prodrugs
Klinik für Tumorbiologie, Breisacher Straße 117, 79106 Freiburg i. Brsg.
Tel.: 0761 206-2930, Telefax.: 0761 206-2905; E-Mail:kratz@tumorbio.uni-freiburg.de*

* book article

+ book

2011

- F. Kratz, I. Fichtner, R. Graeser (2011): Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model. *Investigational New Drugs* [Epub ahead of press]
- M. Calderón, R. Haag, F. Kratz (2011): Säurelabile Nanotransporter als neuartige Drug-Delivery-Systeme zur Behandlung von Krebserkrankungen, *Journal Onkologie* 3, 152-155.
- D. Ren, F. Kratz, S. Wang (2011): Protein nanocapsules containing doxorubicin as a pH-responsive delivery system, *Small*, 7,1051-60.
- Anticancer macromolecular prodrugs in clinical trials – an update (2010), Hot topic edition with contributions by H. Zhao, R.J. Fram, C.S. Young, D. Nowotnik and F. Kratz, *Curr. Bioactive Compounds* 7, (ed. F. Kratz).
- INNO-206 (DOXO-EMCH), an albumin-binding prodrug of doxorubicin for phase II studies against pancreatic, gastric cancer and sarcoma, in Anticancer macromolecular prodrugs in clinical trials – an update (2010), Hot topic edition, *Curr. Bioactive Compounds* 7 (ed. F. Kratz), 33-38.
- *F. Kratz: Drug Delivery in Oncology – Challenges and Perspectives in *Drug Delivery in Oncology – from Research Concepts to Cancer Therapy*, (eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled for October 2011).

- *K. Mross, F. Kratz: Limits of Conventional Chemotherapy in *Drug Delivery in Oncology – from Research Concepts to Cancer Therapy*, (eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled for October 2011).
 - *K. Abu Ajaj, F. Kratz: Clinical Experience with Drug Polymer Conjugates, in *Drug Delivery in Oncology – from Research Concepts to Cancer Therapy*, (eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled October 2011)
 - *K. Hochdörffer, G. Gi Stefano, H. Maeda, F. Kratz: Liver Tumor Targeting, in *Drug Delivery in Oncology – from Research Concepts to Cancer Therapy* (eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled October 2011).
- *A. Warnecke: Self-immolative Systems in *Drug Delivery in Oncology – from Research Concepts to Cancer Therapy* (eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled October 2011).
- *F- Kratz, A. Wunder, B. Elsadek: Serum Proteins as Drug Carriers in *Drug Delivery in Oncology – from Research Concepts to Cancer Therapy* (eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled October 2011).
 - [†]*Drug Delivery in Oncology – from Research Concepts to Cancer Therapy* (eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled for October 2011).
 - G. J. Molderings, M. Raithel, F. Kratz, M. Azemar, B. Haenisch, S. Harzer, J. Homann (2011): Omalizumab treatment of systemic mast cell disease: experiences from four cases. *Internal Medicine*, 50, 611-5.
 - M. Calderón, P Welker, K. Licha, I. Fichtner, R. Graeser, R. Haag, F. Kratz (2011): Development of efficient acid-cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell, *J. Controlled Release*, 151, 295-301.
 - B. Elsadek, R. Graeser, N. Esser, C. Schäfer-Obodozie, C. Tsurumi, A. Warnecke, C. Unger, T. Saleem, F. Kratz (2011): A novel albumin-binding prodrug of doxorubicin with improved efficacy against prostate cancer metastases, *Prostate Cancer and Prostate Disease*, 14, 14-21.

2010

- M. Shama, C. Ryppa, F. Kratz, D. Raucher (2010): Thermally targeted delivery of an acid-sensitive hydrazone derivative of paclitaxel by elastin-like polypeptide, *Investigational New Drugs*, [Epub ahead of press].

- B. Elsadek, R. Graeser, N. Esser, C. Schäfer-Obodozie, K. Abu Ajaj, C. Unger, A. Warnecke, T. Saleem, N. El-Melegy, H. Madkor, F. Kratz (2010): Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an *in vitro* and *in vivo* evaluation study, *Eur. J. Cancer*, *46*, 3434-44.

- I. Müller, F. Kratz, M. Jung, A. Warnecke (2010): Schiff bases derived from p-aminobenzyl alcohol as trigger groups for pH-dependent prodrug activation, *Tetrahedron Letters*, *51*, 4371-4374.

- B. Elsadek, R. Graeser, A. Warnecke, C. Unger, T. Saleem, Nagla El-Melegy, H. Madkor, F. Kratz (2010): Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA), *ACS Med. Chem. Lett.* *1*, 234-238.

- D. Polyak, C. Ryppa, A. Eldar-Boock, K. Licha, F. Kratz, P. Ofek, R. Satchi-Fainaro (2010): PEGylated doxorubicin-E-[c(RGDfK)₂] conjugate for tumor integrin targeting, *Polymers for Advanced Technologies*, *in press*.

- F. Kratz (2010): Albumin, a versatile drug carrier in oncology, *Int. J. Clin. Pharm. Ther.* *48*, 453-455.

- R. Graeser, N. Esser, H. Unger, I. Fichtner, A. Zhu, C. Unger, F. Kratz (2010): INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model, *Investigational New Drugs*, *28*, 14-19.

- M. Calderón, P. Welker, K. Licha, R. Graeser R, F. Kratz, R. Haag (2010): Development of efficient macromolecular prodrugs derived from dendritic polyglycerol, *J. Controlled Release* *20*;148(1):e24-5.

2009

- C. Boga, L. Fiume L, M. Baglioni, C. Bertucci C, C. Farina, F. Kratz, M. Manerba, M. Naldi, G. Di Stefano G (2009): Characterisation of the conjugate of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by ¹³C NMR spectroscopy. *Eur. J. Pharm. Sci.* *38*, 262-269.

- M. Calderon, R. Gräser, F. Kratz, R. Haag (2009): Development of enzymatically cleavable prodrugs derived from dendritic Polyglycerol, *Bioorganic & Medicinal Chemistry Letters* *19*, 3725-3728.

- K. Abu Ajaj, R. Graeser, I. Fichtner, F. Kratz (2009): *In vitro* and *in vivo* study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B, *Cancer Chemotherapy & Pharmacology*, 64, 413-418.
- K. Abu Ajaj, F. Kratz (2009): Development of dual-acting prodrugs for circumventing multidrug-resistance, *Biorg.Med.Chem.Lett.*, 19, 995-1000.
- K. Abu Ajaj, M. Binossek, F. Kratz (2009): Development of protein-binding bifunctional spacers for a new generation of dual-acting prodrugs, *Bioconjugate Chem.*, 20, 390-396.
- K. Abu Ajaj, R. Graeser, I. Fichtner, F. Kratz (2009): *In vitro* and *in vivo* study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B, *Cancer Chemotherapy & Pharmacology*, 64, 413-418.
- M. Calderon, R. Gräser, F.Kratz, R. Haag (2009): Development of enzymatically cleavable prodrugs derived from dendritic Polyglycerol, *Bioorganic & Medicinal Chemistry Letters* 19, 3725-3728.